131.12 -0.10 (-0.08%)
After hours: 7:14PM EST
Previous close | 146.81 |
Open | 146.09 |
Bid | 131.21 x 2900 |
Ask | 132.12 x 1200 |
Day's range | 131.00 - 147.32 |
52-week range | 19.31 - 189.26 |
Volume | 13,580,787 |
Avg. volume | 19,090,858 |
Market cap | 52.458B |
Beta (5Y monthly) | 1.50 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.96 |
Earnings date | 05-May-2021 - 10-May-2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 168.85 |
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
Public health experts have dismissed concerns about J&J' vaccine and stressed its importance.
Johnson & Johnson’s single-dose COVID-19 vaccine is ‘absolutely’ a game changer and will help ensure Americans are vaccinated at a faster pace, according to Dr. Sejal Hathi, physician and clinical fellow at Massachusetts General Hospital.